Archive for the ‘Gout’ Category

Savient Provides Further Information On Top Line Phase 3 Trials Results For Puricase(R) (pegloticase)

Monday, March 3rd, 2008

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced further information related to infusion reactions and deaths for their Phase 3 clinical trials for Puricase(R) (pegloticase) being developed for treatment failure gout patients. Severe and Serious Infusion Reactions Our preliminary analysis indicated that 19 patients or 11% of pegloticase treated patients experienced an infusion reaction ...

EMEA Recommends Marketing Authorisation Of Ipsen’s Adenuric(R) (Febuxostat) For The Treatment Of Chronic Hyperuricaemia In Gout, Europe

Monday, February 25th, 2008

Ipsen (Paris:IPN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) provided a positive opinion for Adenuric® (febuxostat) 80 mg and 120 mg tablets for the treatment of chronic hyperuricaemia in gout and recommended it for marketing authorisation. The CHMP recommendation will ...

New Player In Commitment To Life As A Fat Cell

Saturday, April 7th, 2007

Researchers have discovered a pivotal new player in early events that commit fat cell precursors to becoming full-blown fat, according to a report in the February issue of the journal Cell Metabolism, published by Cell Press. Drugs that block some activities of the enzyme, known as xanthine oxidoreductase (XOR), might ...

Savient Announces Completion Of Patient Enrollment In Phase 3 Trials Of Puricase® For Treatment-Failure Gout

Friday, April 6th, 2007

Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) announced today that it has reached its Phase 3 enrollment target of 200 patients total, in the two replicate placebo-controlled six-month clinical trials. The trials assess the safety and efficacy of Puricase in patients with treatment-failure gout, under the auspices of a Special Protocol Assessment from ...

It’s The Heat And The Humidity: How Each Worsens Gout Symptoms

Monday, November 13th, 2006

Climatic factors such as heat and humidity that lead to dehydration can signal a future attack for gout sufferers, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Washington DC. Gout, caused by deposits of monosodium uric crystals, causes severe pain and swelling of ...

Non-Profit Group Launches Educational Web Site For Gout Sufferers

Monday, November 13th, 2006

The Gout & Uric Acid Education Society, a non-profit group of health care professionals, today launched http://www.gouteducation.org , a valuable educational resource for gout sufferers and their caregivers. The Web site is designed to help gout sufferers enhance their understanding of the disease and its treatments, embrace lifestyle modifications and, ...

Extreme Pain Of Gout Is Detrimental To Quality Of Life & Work , New Poll Shows

Sunday, November 12th, 2006

Results of a new survey show that two-thirds (65 percent) of gout patients ranked their typical gout flares -- defined as a sudden, intense pain -- as either close to, or the worst pain possible and say that the flares last an average of eight days. Seventy-two percent reported having ...